Literature DB >> 33531027

The disease sites of female genital cancers of BRCA1/2-associated hereditary breast and ovarian cancer: a retrospective study.

Takashi Mitamura1,2, Masayuki Sekine3, Masami Arai4, Yuka Shibata5, Momoko Kato5, Shiro Yokoyama6, Hiroko Yamashita7, Hidemichi Watari8, Ichiro Yabe5, Hiroyuki Nomura9, Takayuki Enomoto3, Seigo Nakamura6.   

Abstract

Disease sites of female genital tract cancers of BRCA1/2-associated hereditary breast and ovarian cancer (HBOC) are less understood than non-hereditary cancers. We aimed to elucidate the disease site distribution of genital cancers in women with the germline BRCA1 and BRCA2 pathogenic variants (BRCA1+ and BRCA2+) of HBOC. For the primary disease site, the proportion of fallopian tube and peritoneal cancer was significantly higher in BRCA2+ (40.5%) compared with BRCA1+ (15.4%) and BRCA- (no pathogenic variant, 12.8%). For the metastatic site, the proportion of peritoneal dissemination was significantly higher in BRCA1+ (71.9%) than BRCA- (55.1%) and not different from BRCA2+ (71.4%). With one of the most extensive patients, this study supported the previous reports showing that the pathogenic variants of BRCA1/2 were involved in the female genitalia's disease sites.

Entities:  

Keywords:  BRCA1; BRCA2; Fallopian tube cancer; Hereditary breast and ovarian cancer; Ovarian cancer; Peritoneal cancer

Mesh:

Substances:

Year:  2021        PMID: 33531027      PMCID: PMC7856749          DOI: 10.1186/s12957-021-02151-3

Source DB:  PubMed          Journal:  World J Surg Oncol        ISSN: 1477-7819            Impact factor:   2.754


  6 in total

1.  Clinical characteristics and outcomes of BRCA-associated ovarian cancer: genotype and survival.

Authors:  Joyce Liu; Mihaela C Cristea; Paul Frankel; Susan L Neuhausen; Linda Steele; Verena Engelstaedter; Ursula Matulonis; Sharon Sand; Nadine Tung; Judy E Garber; Jeffrey N Weitzel
Journal:  Cancer Genet       Date:  2012 Jan-Feb

2.  The first Japanese nationwide multicenter study of BRCA mutation testing in ovarian cancer: CHARacterizing the cross-sectionaL approach to Ovarian cancer geneTic TEsting of BRCA (CHARLOTTE).

Authors:  Takayuki Enomoto; Daisuke Aoki; Kana Hattori; Masahisa Jinushi; Junzo Kigawa; Nobuhiro Takeshima; Hitoshi Tsuda; Yoh Watanabe; Kosuke Yoshihara; Toru Sugiyama
Journal:  Int J Gynecol Cancer       Date:  2019-07       Impact factor: 3.437

3.  BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.

Authors:  Kathryn Alsop; Sian Fereday; Cliff Meldrum; Anna deFazio; Catherine Emmanuel; Joshy George; Alexander Dobrovic; Michael J Birrer; Penelope M Webb; Colin Stewart; Michael Friedlander; Stephen Fox; David Bowtell; Gillian Mitchell
Journal:  J Clin Oncol       Date:  2012-06-18       Impact factor: 44.544

4.  BRCA Mutation Status to Personalize Management of Recurrent Ovarian Cancer: A Multicenter Study.

Authors:  Claudia Marchetti; Rossella De Leo; Angela Musella; Marco D'Indinosante; Ettore Capoluongo; Angelo Minucci; Pierluigi Benedetti Panici; Giovanni Scambia; Anna Fagotti
Journal:  Ann Surg Oncol       Date:  2018-08-20       Impact factor: 5.344

5.  Increased incidence of visceral metastases in scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype.

Authors:  Charlie Gourley; Caroline O Michie; Patricia Roxburgh; Timothy A Yap; Sharon Harden; Jim Paul; Kalpana Ragupathy; Radha Todd; Russell Petty; Nick Reed; Richard L Hayward; Paul Mitchell; Tzyvia Rye; Jan H M Schellens; Jan Lubinski; James Carmichael; Stan B Kaye; Melanie Mackean; Michelle Ferguson
Journal:  J Clin Oncol       Date:  2010-04-20       Impact factor: 44.544

6.  Risk factors for lymph node metastasis of ovarian, fallopian tube and primary peritoneal cancer in hereditary breast and ovarian cancer syndrome.

Authors:  Takashi Mitamura; Masayuki Sekine; Masami Arai; Yuka Shibata; Momoko Kato; Shiro Yokoyama; Hiroko Yamashita; Hidemichi Watari; Ichiro Yabe; Hiroyuki Nomura; Takayuki Enomoto; Seigo Nakamura
Journal:  Jpn J Clin Oncol       Date:  2020-12-16       Impact factor: 3.019

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.